ALKS · Alkermes plc.
$49.06
-0.39 (-0.79%)
At close · Aug 14
Market Cap
$8.27B
Shares
167.76M
Alkermes plc. Earnings Call Transcripts
Every quarterly earnings call for Alkermes plc. (ALKS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼14.2%
$252.36M
−$63.97M
'22 Q3
22-11-02
▼6.1%
$304.67M
−$28.25M
'22 Q4
23-02-16
▲3.2%
$287.60M
−$41.84M
'23 Q1
23-04-26
▲123.5%
$617.40M
$237.06M
'23 Q2
23-07-26
▲51%
$380.94M
$47.76M
'23 Q3
23-10-25
▲23.9%
$377.48M
$112.78M
'23 Q4
24-02-15
▲21.8%
$350.37M
$36.83M
'24 Q1
24-05-01
▼35.4%
$399.13M
$91.36M
'24 Q2
24-07-24
▼0.7%
$378.14M
$92.38M
'24 Q3
24-10-24
▲13.9%
$429.99M
$146.50M
'24 Q4
25-02-12
▼12.5%
$306.51M
$22.46M
'25 Q1
25-05-01
▼2.1%
$390.66M
$87.10M
'25 Q2
25-07-29
▲4.2%
$394.19M
$82.76M
'25 Q3
25-10-22
▼10.6%
$384.55M
$49.34M
'25 Q4
26-02-25
▲28.2%
$392.91M
−$66.48M
'26 Q1
26-05-05
LATEST
▲27%
$496.01M
$501,000
'26 Q2
26-07-28
Earnings call
FY26 · Q2
2026-07-28
Q2 2026 Alkermes plc Earnings Conference Call
Revenue
$496.01M
▲ 27% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Alkermes plc. Q1 FY2026 Earnings Call
Confident tone
Avadel acquisition and LUMRYZ integration
ADHD opportunity
Financial guidance and gross-to-net
Revenue
$392.91M
▲ 28.2% YoY Diluted EPS
$-0.40
▼ 407.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Alkermes plc. Q4 FY2025 Earnings Call
Confident tone
Elixorexant (orexin 2 receptor agonist) development
VIVITROL potential generic entry in 2027
Orexin pipeline beyond elixorexant (ALKS 4510, ALKS 7290)
Revenue
$384.55M*
▼ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Alkermes plc. Q3 FY2025 Earnings Call
Confident tone
Orexin Platform / Alixorexton
Proprietary Product Portfolio
Financial Performance and Guidance Raise
Revenue
$394.19M
▲ 4.2% YoY Diluted EPS
$0.49
▼ 10.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Alkermes plc. Q2 FY2025 Earnings Call
Confident tone
Alixorexton / Vibrance 1 Phase II results
Commercial portfolio growth
Phase III preparation and dosing
Revenue
$390.66M
▼ 2.1% YoY Diluted EPS
$0.52
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Alkermes plc. Q1 FY2025 Earnings Call
Positive tone
ALKS 2680 Phase 2 orexin program (Vibrance-1 and Vibrance-2)
Commercial performance of proprietary products
Macroeconomic and policy landscape (tariffs, Medicaid, FDA)
Revenue
$306.51M
▼ 12.5% YoY Diluted EPS
$0.13
▼ 38.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Alkermes plc. Q4 FY2024 Earnings Call
Confident tone
ALKS 2680 Orexin Program
LYBALVI Growth and Competition
Financial Performance and Profitability
Revenue
$429.99M*
▲ 13.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Alkermes plc. Q3 FY2024 Earnings Call
Confident tone
Proprietary product growth (VIVITROL, ARISTADA, LYBALVI)
Operating efficiency and profitability / cost discipline
ALKS 2680 orexin 2 receptor agonist program
Revenue
$378.14M
▼ 0.7% YoY Diluted EPS
$0.55
▲ 96.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Alkermes plc. Q2 FY2024 Earnings Call
Confident tone
ALKS 2680 Orexin program
LYBALVI growth and access
Proprietary product portfolio performance
Revenue
$399.13M
▼ 35.4% YoY Diluted EPS
$0.53
▼ 61.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Alkermes plc. Q1 FY2024 Earnings Call
Positive tone
Proprietary product portfolio growth
LYBALVI launch trajectory and prescriber expansion
2024 financial guidance reiteration and outlook
Revenue
$350.37M
▲ 21.8% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Alkermes plc. Q4 FY2023 Earnings Call
Confident tone
LYBALVI Commercial Performance
ALKS 2680 Orexin Pipeline
VIVITROL Growth and Mix
Revenue
$377.48M*
▲ 23.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Alkermes plc. Q3 FY2023 Earnings Call
Revenue
$380.94M
▲ 51% YoY Diluted EPS
$0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Alkermes plc. Q2 FY2023 Earnings Call
Revenue
$617.40M
▲ 123.5% YoY Diluted EPS
$1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Alkermes plc. Q1 FY2023 Earnings Call
Revenue
$287.60M
▲ 3.2% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Alkermes plc. Q4 FY2022 Earnings Call
Revenue
$304.67M*
▼ 6.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Alkermes plc. Q3 FY2022 Earnings Call
Revenue
$252.36M
▼ 14.2% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Alkermes plc. Q2 FY2022 Earnings Call
Revenue
$276.22M
▼ 9.1% YoY Diluted EPS
$-0.18
▼ 1900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Alkermes plc. Q1 FY2022 Earnings Call
Revenue
$278.55M
▲ 10.8% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
Alkermes plc. Q4 FY2021 Earnings Call
Revenue
$324.46M*
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Alkermes plc. Q3 FY2021 Earnings Call
Revenue
$294.14M
▲ 11% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Alkermes plc. Q2 FY2021 Earnings Call
Revenue
$303.72M
▲ 22.7% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Alkermes plc. Q1 FY2021 Earnings Call
Revenue
$251.43M
▲ 2.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Alkermes plc. Q4 FY2020 Earnings Call
Revenue
$280.00M*
▼ 32.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Alkermes plc. Q3 FY2020 Earnings Call
Revenue
$265.01M
▲ 3.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Alkermes plc. Q2 FY2020 Earnings Call
Revenue
$247.53M
▼ 11.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Alkermes plc. Q1 FY2020 Earnings Call
Revenue
$246.22M
▲ 10.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Alkermes plc. Q4 FY2019 Earnings Call
Revenue
$412.73M*
▲ 30.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1520262
CUSIP
G01767105
13F (30d)
407 filings
389 filers
Visit website
Investor relations